Sequoia Financial Advisors LLC Purchases 1,080 Shares of Hologic, Inc. (NASDAQ:HOLX)

Sequoia Financial Advisors LLC lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 8,468 shares of the medical equipment provider’s stock after buying an additional 1,080 shares during the period. Sequoia Financial Advisors LLC’s holdings in Hologic were worth $610,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. First Horizon Advisors Inc. lifted its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Brooklyn Investment Group lifted its position in shares of Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after buying an additional 145 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC grew its position in Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after acquiring an additional 169 shares during the last quarter. Finally, Loomis Sayles & Co. L P raised its stake in Hologic by 29.3% during the third quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock worth $66,000 after acquiring an additional 183 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HOLX. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a report on Monday, February 3rd. Raymond James reaffirmed an “outperform” rating and set a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada cut their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Argus cut Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Morgan Stanley cut their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $84.62.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $61.82 on Tuesday. The company has a market capitalization of $13.87 billion, a PE ratio of 19.50, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67. The firm has a fifty day simple moving average of $66.94 and a 200 day simple moving average of $74.51.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.